HBMN.SW HBM Healthcare (SIX) CHF 237.00 pre-earnings 21 Jan 2026: dividend, NAV eye
We see HBMN.SW stock trading at CHF 237.00 intraday on 21 Jan 2026 as investors position for an earnings update due 23 Jan 2026. Traders will watch the announced EPS 13.66 and PE 17.31 alongside the fund’s NAV and upcoming dividend signals. Liquidity is light with volume 3367.00 versus an average of 8582.00, so intraday swings can be amplified. We focus on how valuation, dividend yield and NAV disclosure could move the price into or out of its year high CHF 239.00 band.
HBMN.SW stock: earnings preview and what to watch
HBMN.SW stock faces an earnings announcement scheduled for 23 Jan 2026 (company time). Investors will parse the report for net realised gains, NAV updates and any change to distribution policy.
Key figures to watch in the release include EPS 13.66, reported book value per share CHF 251.31, and dividend per share CHF 7.50. Each figure links directly to valuation and the fund-style performance that drives HBM Healthcare Investments AG’s share price.
HBMN.SW stock: recent performance and sector context
HBMN.SW stock is up 26.07% over 12 months and 6.29% year-to-date, reflecting strong re-rating versus earlier lows. The short-term trend is supported by a 50-day average CHF 217.25 and a 200-day average CHF 187.13.
Against the Swiss Financial Services sector average PE 16.70, HBMN.SW’s PE 17.31 sits marginally above the peer set, while its sector (Financial Services / Asset Management) shows muted YTD performance that gives HBMN room to outperform if healthcare holdings deliver positive exits.
HBMN.SW stock: valuation and fundamentals
HBMN.SW displays conservative balance-sheet metrics with book value per share CHF 251.31 and price-to-book 0.94, indicating the market values the company slightly below net assets. Market capitalisation stands at CHF 1,579,929,736.00.
Profitability ratios show ROE 5.65% and an attractive dividend yield near 3.17%, supported by a payout ratio of 35.52%. Debt is low with debt-to-equity 0.10, limiting financial leverage risk for the portfolio vehicle.
HBMN.SW stock: technicals and intraday trading setup
Intraday range is CHF 234.00–CHF 237.00 with a previous close of CHF 235.00, and a light trade cadence at volume 3367.00 versus an average 8582.00, so directional moves may be exaggerated. Momentum indicators show an RSI of 67.73 and ADX 34.98, signalling a strong short-term trend.
Traders should note Bollinger upper band at CHF 235.57 and ATR CHF 5.20 when sizing positions. Suggested market-style targets are a near-term technical target CHF 238.00, a base case CHF 255.00, and a conservative downside support CHF 210.00, framed as scenario-based reference points rather than formal analyst guidance.
Meyka AI rates HBMN.SW with a score out of 100 and forecast
Meyka AI rates HBMN.SW with a score out of 100: 70.04 / Grade B+ — Suggestion: BUY. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst-style consensus.
Meyka AI’s forecast model projects a monthly price CHF 238.04, quarterly CHF 181.09, and yearly CHF 109.01. Versus the current CHF 237.00, the model implies a near-term upside of 0.44% and a quarterly downside of -23.56% and a one-year downside of -53.99%. Forecasts are model-based projections and not guarantees. For live filings and corporate detail, see the company website source and market platform source.
HBMN.SW stock: principal risks and opportunities
Primary risks for HBMN.SW stock include NAV volatility from private exits, thin intraday liquidity, and sensitivity to healthcare exit markets which can swing realised gains materially. Concentration in mid-market healthcare names increases idiosyncratic risk.
Opportunities include recurring dividend income (dividend per share CHF 7.50), a strong book value cushion, low leverage and the potential for follow-on realisations or IPO exits to lift NAV. We note the Swiss healthcare sector’s recent positive momentum can provide a supportive backdrop.
Final Thoughts
HBMN.SW stock trades at CHF 237.00 on SIX on 21 Jan 2026 with earnings due on 23 Jan 2026, placing NAV and dividend signals at the centre of near-term moves. Valuation metrics show a price-to-book 0.94 and PE 17.31, while cashflows and operating metrics remain fund-specific. Meyka AI’s grade (70.04, B+, Suggestion: BUY) reflects solid fundamentals, conservative leverage and sector exposure but flags valuation sensitivity to exit timing. Meyka AI’s forecast model projects a monthly target CHF 238.04 (implied +0.44% vs current price) but also shows material downside in longer horizons; forecasts are model-based projections and not guarantees. For active traders the technical setup and light liquidity argue for careful size control; for income-minded investors the 3.17% dividend yield and strong book value are confirming signals. We will watch the earnings release for NAV detail and realised gains that can drive a re-rating or correction.
FAQs
When will HBMN.SW earnings be announced and why does it matter?
HBMN.SW earnings are scheduled for 23 Jan 2026. The report matters because NAV revisions, realised gains and dividend guidance can cause immediate price moves given the stock’s light intraday volume and fund-style holdings.
What is the current valuation and dividend picture for HBMN.SW stock?
HBMN.SW trades at PE 17.31 and price-to-book 0.94 with dividend per share CHF 7.50, implying a yield near 3.17%. These metrics show a modest valuation and income component against book value.
How does Meyka AI rate HBMN.SW stock and what does the forecast show?
Meyka AI rates HBMN.SW 70.04 (Grade B+, Suggestion: BUY). The model projects monthly CHF 238.04 (+0.44%) and flags larger medium-term downside; forecasts are projections, not guarantees.
What are the main risks for HBMN.SW stock after the earnings release?
Key risks include NAV volatility from limited exits, thin trading liquidity (volume 3367.00), and concentration in mid-market healthcare investments that can amplify swings in realised gains and share price.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
